4-Amino-1-benzylpiperidine-4-carboxylic acid hydrochloride | 150435-80-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 4-Amino-1-benzylpiperidine-4-carboxylic acid hydrochloride
• 英文别名: 4-amino-1-benzylpiperidine-4-carboxylic acid;hydrochloride
• CAS: 150435-80-6
• 化学式: C13H19ClN2O2
• 分子量: 270.75
• InChiKey: CAVZLOVNIHCTEG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.49
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  66.6
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  1-苄基-4-氨基-4-哌啶甲酸 、 氯化亚砜 以 甲醇 为溶剂， 反应 21.0h， 以to give 6.14 g of 4-amino-1-benzylpiperidine-4-carboxylic acid hydrochloride ax58 as a hygroscopic white solid的产率得到4-Amino-1-benzylpiperidine-4-carboxylic acid hydrochloride
  参考文献：
  名称：

  Compounds comprising an oxazoline or thiazoline moiety, processes for making them, and their uses

  摘要：

  本发明涉及具有氧唑啉或噻唑啉基团的化合物，制备它们的方法，包含所述化合物的制药组合物以及其作为H3受体配体的用途，其中A1是CH、C(CH3)或N；R1是氢或卤素；R2是(II)；A2是O或S；R3是氢、卤素、C1-4烷基或C1-4烷氧基；R4是氢、卤素、C1-4烷基、C1-4烷氧基、三氟甲基或—O—(CH2)n-NR12aR，其中—O—(CH2)n-NR12aR12b中的每个CH2可以选择性地由一个或两个C1-4烷基取代；R5是氢或—O—(CH2)m—NR13aR13b，其中—O—(CH2)m—NR13aR13b中的每个CH2可以选择性地由一个或两个C1-4烷基取代，且R4和R5中至少有一个应为—O—(CH2)n-NR12/13aR12/13b基团。

  公开号：

  US07863450B2

文献信息

• Compounds Comprising an Oxazoline or Thiazoline Moiety, Processes for Making Them, and Their Uses
  申请人：Leurs Regorius

  公开号：US20080161331A1

  公开（公告）日：2008-07-03

  The present invention relates to compounds comprising an oxazoline or thiazoline moiety, processes for preparing them, pharmaceutical compositions comprising said compounds and their uses as H 3 -receptor ligands, (I), wherein A 1 is CH C(CH 3 ) or N; R 1 is hydrogen or halogen; R 2 is (II); A 2 is O or S; R 3 is hydrogen, halogen, C 1-4 alkyl or C 1-4 alkoxy; R 4 is hydrogen, halogen, C 1-4 alkyl, C 1-4 alkoxy, trifluoromethyl or —O—(CH 2 )n-NR 12a R each CH 2 in —O—(CH 2 )n-NR 12a R 12b being optionally substituted by one or two C 1-4 alkyl; R 5 is hydrogen or —O—(CH 2 ) m —NR 13a R 13b , each CH 2 in —O—(CH 2 ) m —NR 13a R 13b being optionally substituted by one or two C 1-4 alkyl, and at least one of R 4 and R 5 should be a —O—(CH 2 )n-NR 12/13a R 12/13b group.

  本发明涉及包含氧唑啉或噻唑啉基团的化合物，制备它们的方法，包含所述化合物的制药组合物以及它们作为H3受体配体的用途，其中A1为CH、C(CH3)或N；R1为氢或卤素；R2为(II)；A2为O或S；R3为氢、卤素、C1-4烷基或C1-4烷氧基；R4为氢、卤素、C1-4烷基、C1-4烷氧基、三氟甲基或-O-(CH2)n-NR12aR12b，其中-O-( )n-NR12aR12b可以选择地被一个或两个C1-4烷基取代；R5为氢或-O-( )m-NR13aR13b，每个-O-( )m-NR13aR13b中的 可以选择地被一个或两个C1-4烷基取代，并且R4和R5中至少有一个应为-O-( )n-NR12/13aR12/13b基团。
• COMPOUNDS COMPRISING AN OXAZOLINE OR THIAZOLINE MOIETY, PROCESSES FOR MAKING THEM, AND THEIR USES
  申请人：UCB Pharma, S.A.

  公开号：EP1866294A1

  公开（公告）日：2007-12-19
• US7863450B2
  申请人：——

  公开号：US7863450B2

  公开（公告）日：2011-01-04
• [EN] COMPOUNDS COMPRISING AN OXAZOLINE OR THIAZOLINE MOIETY, PROCESSES FOR MAKING THEM, AND THEIR USES<br/>[FR] COMPOUNDS COMPRISING AN OXAZOLINE OR THIAZOLINE MOIETY, PROCESSES FOR MAKING THEM, AND THEIR USES
  申请人：UCB SA

  公开号：WO2006103057A1

  公开（公告）日：2006-10-05

  [EN] The present invention relates to compounds comprising an oxazoline or thiazoline moiety, processes for preparing them, pharmaceutical compositions comprising said compounds and their uses as H₃-receptor ligands, (I), wherein A¹ is CH C(CH₃) or N; R¹ is hydrogen or halogen; R² is (II); A² is O or S; R³ is hydrogen, halogen, C₁
  [FR] The present invention relates to compounds comprising an oxazoline or thiazoline mmoiety, processes for preparing them, pharmaceutical compositions comprising said compounds and their uses as H₃-receptor ligands, Formula (I), wherein A¹ is CH C(CH₃) or N; R¹ is hydrogen or halogen; R² is Formula (II); A² is O or S; R³ is hydrogen, halogen, C_1-4 alkyl or C_1-4 alkoxy; R⁴ is hydrogen, halogen, C_1-4 alkyl, C_1-4 alkoxy, trifluoromethyl or -O-(CH₂)n- NR^12a